RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
98 hedge funds and large institutions have $637M invested in RAPT Therapeutics in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 17 closing their positions.
9,931% more call options, than puts
Call options by funds: $10.8M | Put options by funds: $108K
15% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 33
4% more capital invested
Capital invested by funds: $611M → $637M (+$26.2M)
0.25% more ownership
Funds ownership: 12.14% → 12.39% (+0.25%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less funds holding
Funds holding: 106 → 98 (-8)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$19.2M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$8.44M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.11M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.35M |
| 5 |
EC
Euclidean Capital
New York
|
+$2.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.33M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.98M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.17M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$4.99M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.69M |
RAPT Hedge Fund Activity: Q2 2023 in Review
98 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2023, worth a combined $637M — up 4.3% from $611M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RAPT and 9 opened new positions — a net loss of 8 holders — while 33 trimmed existing stakes and 38 added.
The largest buyer was Braidwell, opening a new position worth an estimated $19.2M. The largest seller was Cormorant Asset Management, cutting an estimated $6.33M.
- 98 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2023, down from 106 in Q1 2023.
- Funds reported $637M of RAPT Therapeutics stock for Q2 2023, up 4.3% quarter-over-quarter.
- 9 funds opened new RAPT Therapeutics positions in Q2 2023 and 17 closed out, a net change of -8 holders.
- The largest RAPT Therapeutics buyer in Q2 2023 was Braidwell, an estimated $19.2M added.
- The largest RAPT Therapeutics seller in Q2 2023 was Cormorant Asset Management, an estimated $6.33M sold.
Based on aggregated 13F filings for Q2 2023.